
Opinion|Videos|March 31, 2025
Long-Term Outcomes and Treatment Guidelines in DLBCL Management
Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse large B-cell lymphoma (DLBCL) treatment, offering insights on how to interpret and apply these recommendations in various patient scenarios.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please explain how the 5-year outcomes have impacted polatuzumab’s position in current NCCN guidelines for DLBCL treatment.
- How do you interpret and apply these guideline recommendations across patient scenarios?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















